Introduction
Colon cancer is one of the most frequent causes of cancer death worldwide. 1 Despite recent advances of diagnosis and treatment strategies in clinical and experimental oncology, 2 the mortality rate of colon cancer remains high. Therefore, it is urgent to investigate the molecular mechanisms underlying the progression of colon cancer and to identify novel therapeutic targets for early diagnosis and treatment of colon cancer.
MIEN1, a novel oncogene located in the 17q12-21 region of the human chromosome, 3 is often dysregulated in various cancer types. [4] [5] [6] MIEN1 expression is upregulated in different stages and grades of prostate cancer phenotypes and involves tumor progression of prostate cancer. 3, 7, 8 MIEN1 was also upregulated and can be used as a novel breast cancer biomarker in patients with metastatic progression to lung and liver, and siRNA-mediated knockdown of MIEN1 induces apoptosis of breast cancer cells. 4, 9 Recently, MIEN1 was reported to be overexpressed in colorectal cancer tissue, and MIEN1 expression level was closely associated with tumor serosal invasion, lymph node metastasis, and an advanced Dukes stage. 10 However, the role of MIEN1 in colon cancer progression remains unknown.
MicroRNA (miRNA) is an abundant group of small noncoding RNA (with about 22 nucleotides); it controls expression of the target gene by binding to the 3′ untranslated submit your manuscript | www.dovepress.com
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ren et al region (UTR) of their target genes and plays an important role in a variety of biological processes, including cell proliferation, apoptosis, differentiation, invasion, migration, and so on. [11] [12] [13] [14] A growing number of studies have found that miRNAs are dysregulated in a variety of cancer types, and that these play a critical role in tumorigenesis. [15] [16] [17] [18] [19] [20] Recent studies demonstrated that some miRNAs are critical regulators in the development and progression of cancer, including colon cancer. [21] [22] [23] Therefore, identification of novel miRNAs that are involved in colon cancer progression may contribute to the development of prognostic biomarker and therapeutic strategy for colon cancer.
miR-136 has been reported to be dysregulated in various cancer types and involves tumor progression. 24 It was overexpressed in murine lung cancers via miRNA microarray expression profiling. 25 Moreover, upregulated miR-136 was also observed in human non-small-cell lung cancer (NSCLC). 26 miR-136 also functions as a tumor suppressor and suppresses mesenchymal metastasis in triple-negative breast cancer. 27 However, the expression and biological function of miR-136 in colon cancer remain to be established.
In this study, we for the first time identified MIEN1 as a direct target of miR-136, which revealed the deregulated expression of miR-136 in colon cancer and investigated the function of miR-136 on cell migration and invasion in the progression of colon cancer. In conclusion, miR-136 acts as a tumor suppressor and may serve as a potential therapeutic target in colon cancer. 
Materials and methods human tissue specimens
cell culture and transfection
Human colon cancer cell lines (SW-480 and SW-620) purchased from ATCC were grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% (vol/vol) fetal bovine serum and 2 mM of l-glutamine. Cultures were maintained at 37°C in a humidified atmosphere with 5% CO 2 .
SW-480 and SW-620 cells were seeded in 12-well plates and transiently transfected with miR-136 mimic, miR-136 inhibitor, mimic negative control (mimic control), and inhibitor negative control (inhibitor control) sequences using Lipofectamine 2000 (Thermo Fisher Scientific, Waltham, MA, USA). SW-480 and SW-620 cells were contransfected with miR-136 mimic and MIEN1 plasmid. The cells were harvested at 24 h for further assay.
Quantitative real-time polymerase chain reaction
We used Trizol solution (Sigma-Aldrich, St Louis, MO, USA) to extract RNA from cells and human colon cancer tissue, which was then reverse-transcripted to obtain complementary DNA (cDNA; Primescript RT Reagent kit, Takara, Japan) according to the manufacturer's instructions. The expression levels of miRNA and mRNA were then detected by SYBR Premix Ex Taq II (Takara, Japan) using the CFX96™ Real-Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA, USA). The primer sequences of miR-136 and MIEN1 were described previously. 26, [28] [29] [30] luciferase reporter gene assays
The 3′-UTR of MIEN1 was amplified and subcloned into pGL3 luciferase promoter vector (Promega, Madison, WI, USA), and the mut-MIEN1 was built by mutating the binding site of miR-136 on the 3′-UTR of MIEN1 as previously described. 31 The MIEN1/pGL3 or mut-MIEN1/pGL3 was cotransfected with miR-136 mimics or inhibitors into HEK293 cells. The cells were harvested at 48 h, and a dualluciferase reporter assay kit (Promega) was used to detect the relative luciferase activity. All experiments were performed at least three times.
Western blotting analysis
We used radioimmunoprecipitation assay (Thermo Fisher Scientific) to get the whole cell extracts, and then, the protein samples were separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (10%) and incubated with polyclonal (rabbit) anti-MIEN1, anti-Akt, anti-p-Akt, and anti-p-NF-κB antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) overnight at 4°C, and with goat anti-rabbit IgG (Pierce, Rockford, IL, USA) secondary antibody for 1 h at room temperature. ECL detection systems (SuperSignal West Femto, Pierce, Rockford, IL, USA) were used for detection.
invasion and migration assay
A transwell invasion assay was used here to detect invasion capability of NSCLC cells. Cells were transferred to the upper chamber and incubated at 37°C containing 5% CO 2 . Then, we observed the procedures of cellular growth at 72 h. The transwell migration chambers were used to evaluate cell invasion. A wound healing assay was also used to detect cell migration capability as described previously. 32 
statistical analysis
Each experiment was repeated at least three times. Data were shown as mean ± standard deviation (SD) and analyzed using SPSS 19.0. Statistical comparisons between groups were made using Student's t-test and a two-tailed test, where P,0.05 was considered to be statistically significant.
Results
Mien1 is a direct target of mir-136 in colon cancer
In this study, we used TargetScan, PicTar, and miRanda and found that the 3′-UTR of MIEN1 has a binding site for miR-136 ( Figure 1A ). Next, we used a luciferase reporter assay to confirm this prediction. As shown in Figure 1B , miR-136 mimics significantly decreased the luciferase activity of the wide-type MIEN1/pGL-3, whereas miR-136 inhibitors observed reverse effects. Moreover, both miR-136 mimics and miR-136 inhibitors failed to affect the luciferase activity of the mutant-type MIEN1/pGL-3.
To further characterize the effects of miR-136 on MIEN1 expression, we transfected the mimics or inhibitors of miR-136 into SW-480 and SW-620 cells to overexpress or knockdown miR-136, and then analyzed the MIEN1 expression levels by quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot assay. As shown in Figure 1B , miR-136 mimics significantly decreased MIEN1 expression at both the mRNA and protein levels in colon cancer cells. In contrast, miR-136 inhibitors increased MIEN1 expression in colon cancer cell lines. These data Figure 2A and B, the expression level of miR-136 was markedly decreased in colon cancer tissues compared with the corresponding normal tissue. Next, we analyzed the clinicopathological significance of miR-136 in colon cancer tissues (Table 1) . Our results showed that there was no significant association between miR-136 expression and the parameters, including age and gender, but we found that the miR-136 levels were negatively associated with tumor size, lymph node invasion, TNM stage, and metastasis. Consistent with previous studies, 10 we also confirmed that MIEN1 was overexpressed in colon cancer tissue samples. Additionally, we investigated the relationship of miR-136 expression with MIEN1 expression ( Figure 2C ). As expected, miR-136 expression was negatively correlated with that of MIEN1 in colon cancer samples (R=−0.739), suggesting that miR-136 negatively regulated MIEN1 expression.
mir-136 represses the invasion, migration, and eMT of colon cancer cells by inhibiting Mien1
To further analyze the function of miR-136 and MIEN1 in colon cancer progression, we upregulated miR-136 and MIEN1 to detect the migratory and invasive capability of colon cancer cells. We first used miR-136 mimics to upregulate miR-136 expression, and miR-136 inhibitors to downregulate miR-136 expression and contransfected miR-136 mimics with MIEN1 to rescue MIEN1 expression ( Figure 1A and B) . As shown in Figure 3C , the wound healing assay showed that knockdown miR-136 by miR-136 inhibitors promoted cell migration in both SW-480 and SW-620 cells. The overexpressed miR-136 by miR-136 mimics in both SW-480 and SW-620 cells obviously inhibited cell migration, effect of miR-136 mimics ( Figure 3D ). These data strongly suggested that miR-136 inhibits the migratory and invasive ability of colon cancer cells by targeting MIEN1.
The epithelial-to-mesenchymal transition (EMT) is crucial to cancer progression and metastasis. In this study, to reveal the potential of miR-136 in the EMT process, we detected the expression levels of E-cadherin, N-cadherin, and Vimentin (EMT-related proteins) using a Western blot assay. As shown in Figure 3E , miR-136 mimics evidently induced E-cadherin expression in the miR-136 mimics group, while the inhibition of miR-136 mimics was reversed by contransfecting with MIEN1 in colon cancer cells. Moreover, miR-136 remarkably reduced N-cadherin and vimentin expression, which was attenuated by contransfecting with MIEN1. These indicated that miR-136 represses EMT by targeting MIEN1.
mir-136 suppressed the akt/nF-κB signaling pathway in colon cancer
Previous studies suggest that MIEN1 plays an important regulatory role in phosphorylation of AKT, 6 which subsequently activated the NF-κB signaling pathway. 5 Here, we speculated that miR-136 might regulate the expression of downstream effectors of MIEN1. As shown in Figure 4A -C, miR-136 evidently decreased p-AKT and p-NF-κB protein expression levels in colon cancer. Conversely, miR-136 inhibitors-induced miR-136 knockdown increased p-AKT and p-NF-κB expression. which was rescued by overexpression of MIEN1. Consistent with the above-mentioned results, transfection of miR-136 mimics significantly decreased the invasion capabilities of colon cancer cells, which was rescued by overexpression of MIEN1, while an miR-136 inhibitor showed the opposite 
Discussion
MIEN1 located in the 17q12 region of the human chromosome, next to the Her-2/neu loci, 3 has reported to be dysregulated in various cancer types. [4] [5] [6] For example, MIEN1 was reported to be overexpressed in colorectal cancer tissue and closely associated with tumor serosal invasion, lymph node metastasis, and an advanced Dukes stage. 10 However, only a few studies have investigated the potential molecular mechanism of MIEN1 in colon cancer progression. Here, we for the first time demonstrated that MIEN1 was a direct target of miR-136, which is involved in colon cancer invasion, migration, and EMT by repressing MIEN1 expression.
Many recent studies have demonstrated the critical role of miRNAs in tumorigenesis and progression via regulating target gene expression. 33, 34 MIEN1 as a novel oncogene was also reported to be regulated by miRNAs in several cancer types. 8, 30 Here, bioinformatics databases predict that miR-136, as an upstream miRNA, binds to the 3′-UTR of MIEN1 directly, which was also confirmed by luciferase assay. Moreover, miR-136 mimics significantly inhibited miR-136 functions as a regulator, dysregulated in various cancer types, and involves tumor progression. 24 MiRNA microarray expression profiling showed that miR-136 was prominently overexpressed in murine lung cancers. 25 miR-136 was also reported to be significantly upregulated in human NSCLC primary tumors. 26 These studies demonstrated miR-136 as an oncogene. However, other study showed that miR-136 functions as a tumor suppressor by suppressing mesenchymal invasion and metastasis in triple-negative breast cancer. 27 Therefore, the expression and role of miR-136 are controversial, as they vary in different types of cancer. Here, we found that the expression level of miR-136 was markedly decreased in colon tissues, and its expression level was negatively associated with tumor size, lymph node invasion, TNM stage, and metastasis in the clinicopathological characteristic assay, indicating the important role of miR-136 in the progression of colon cancer. Additionally, these results were further confirmed by statistical analysis that the expression level of miR-136 was negative with that of MIEN1 in colon cancer. Similarly, Yang et al showed that miR-136 may play a tumor-suppressive role by repressing EMT via targeting Smad2 and Smad3 in lung adenocarcinoma. 35 Next, the functional assay showed that miR-136 mimics decreased cell invasion, migration, and EMT. In addition, the Akt/NF-κB signaling pathway, the downstream regulator of MIEN1, was regulated by miR-136. miR-136 repressed colon cancer invasion and migration, which was rescued by overexpressed MIEN1.
Taken together, this study demonstrated that miR-136 suppressed colon cancer cell invasion, migration, and EMT progression by directly targeting MIEN1. Moreover, the expression of miR-136 was downregulated in colon cancer tissues, and miR-136 expression level was negatively associated with tumor size, lymph node invasion, and TNM stage of colon cancer. In conclusion, we demonstrated the regulatory mechanism underlying MIEN1 upregulation in
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